A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis.

Trial Profile

A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Alefacept (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 20 Mar 2012 Planned number of patients changed from 50 to 55 as reported by European Clinical Trials Database record.
    • 20 Mar 2012 This trial has been discontinued in Bulgaria, and Latvia as reported by European Clinical Trials Database record.
    • 15 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top